Navigation Links
Milwaukee area biotech ZyStor seeks more funding

Wauwatosa, Wis. ZyStor Therapeutics, Inc. will seek additional venture funding this year in advance of filing for an investigational new drug application, president and CEO Loren G. Peterson said.

Peterson explained the company's plans during an informal gathering at the Innovation Monday program. He said ZyStor, which is developing enzyme repl......

Full article >>> painful disabilities.

Such disabilities are rare, but those afflicted can die at an early age, and existing drug therapies have proven inadequate. "I think one child born in Wisconsin each year has an LSD, which is how rare they are," Peterson said.

To be effective, the therapeutic enzyme must be delivered to the appropriate cells in tissues where the storage defect manifests its......

Full article >>> he disease. Genzyme Corp., the Massachusetts life science company that acquired Madison's Bone Care International, has built a $2.7 billion corporation on the treatment of rare genetic diseases, Broderick noted.

ZyStor hopes to partner with leading pharmaceutical companies for the development of enzyme replacement therapies. The company has an RFP out to prospective clinical contract manu......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 04/18/06


Related biology technology :

1. Bruce Maas named CIO at UW-Milwaukee
2. Milwaukee takes another step in electronic patient data exchange
3. Company still behind schedule on Milwaukee wireless project
4. Chicago-Milwaukee "mega-metro" infrastructure improvements are critical
5. Milwaukee software developer gains bottom line, loses waistline
6. Education is fundamental to Milwaukees growth
7. Grow Milwaukee includes millions for tech funding
8. AT&T tech rollout will bring 200 jobs to Milwaukee
9. Bandwidth provider expands in Milwaukee
10. Handicapping Milwaukees wireless initiative
11. Businesses could bridge digital divide in Milwaukee with used computers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 24, 2017  VWR Corporation (NASDAQ: VWR), the leading global ... production customers, today reported its financial results for the fourth ... Highlights: 4Q16 record quarterly net sales ... an organic basis. 4Q16 EMEA-APAC ... basis, while the Americas net sales increased 2.5%, or down ...
(Date:2/23/2017)... -- Financial Highlights ... unaudited)Three Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$   ... Product Revenue 3539(10)%9498(4)%Kuvan Net Product ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
Breaking Biology News(10 mins):